Dementia Drug Research Faces Setback Amid Participant Shortage

Research into new dementia drugs is on the verge of a revolution, but progress could be significantly hampered by a critical shortage of participants for clinical trials, according to a new report.

For the first time, the pipeline of innovative diagnostic tests and treatments for Alzheimer's disease and other dementias is rapidly expanding. However, this progress risks grinding to a halt unless more people volunteer for clinical trials and restrictive eligibility criteria are reviewed, Alzheimer's Disease International (ADI) warns.

The UK-based federation of 105 global Alzheimer's charities has published a report revealing that more than 158 potential drugs are currently being evaluated across over 192 trials worldwide. These trials collectively require an estimated 55,000 participants to continue. Yet, stringent screening criteria exclude many willing volunteers, meaning approximately 350,000 individuals must come forward to meet recruitment needs.

The situation in the UK is particularly concerning, with only 551 people currently enrolled in dementia trials, a stark contrast to the around 24,000 participants in cancer trials, as heard at the Alzheimer's Society annual conference this week.

"This is a moment of real hope for dementia research," said Chris Lynch, acting chief executive of ADI. "After decades of frustration, clinical trials have shown for the first time that new treatments can slow the progression of Alzheimer's disease, and a burgeoning pipeline of treatment trials brings real hope. We are on the cusp of a revolution in dementia diagnostics and treatments, but major barriers to recruiting trial participants risk slowing progress."

The ADI report, titled 'A new era in dementia clinical trials,' highlights that barriers to participation often begin long before individuals reach a research center. Delayed diagnosis, limited access to specialist testing, travel costs, language barriers, and the potential need for a care partner to be present can all prevent people from being considered for a trial. These challenges are further complicated when trying to recruit volunteers in the pre-symptomatic or at-risk stages of dementia.

Professor Craig Ritchie, chief executive of Scottish Brain Sciences and a researcher involved in the report, described the pace of progress as a pivotal moment for brain health research. "For the first time, there is a growing pipeline of treatments and tests that have the potential to detect and then delay, slow, and perhaps even prevent Alzheimer's disease," he stated. "The opportunity before us is extraordinary. Advances that once felt distant are now becoming reality, bringing hope to millions of people and families affected by a range of neurodegenerative diseases."

Michelle Dyson, chief executive of Alzheimer's Society, emphasized the importance of timely diagnosis and accessible trials. "We know many people are keen to take part in research but are diagnosed too late and never given the opportunity, while others face practical barriers that make participation difficult," she said. "That's why Alzheimer's Society and the UK Dementia Trials Network established a team of Dementia Research Nurses, to help more people living with dementia access clinical trials. The science is flying – but unless diagnosis and access to trials improves, we won't see these breakthroughs reaching the people who need them most."

New classes of dementia drugs have shown the ability to reverse the underlying cause of the disease and extend quality of life, but they are most effective when administered early. Prompt diagnosis is therefore essential. While some new treatments have been approved for use in the UK, they are not yet available on the NHS. Researchers anticipate that upcoming treatments could be even more effective and cost-efficient, increasing their likelihood of NHS approval.

A Department of Health and Social Care spokesperson affirmed the UK's commitment to becoming a world leader in dementia research, with plans to boost clinical trial participation to 2,000 people over the next five years. "We want trials to be available across the country, so everyone has the same chance to participate in life-changing research," the spokesperson said. "We now have 158 drugs for this condition being tested in clinical trials, compared to only 24 a decade ago, and we are supporting numerous studies through the National Institute for Health and Care Research."